Takeda seals $1.2 billion oncology deal with Innovent Biologics

Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent

LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea

Presbyopia, the age-related loss of near vision, could soon be treated successfully

Alkem launches globally acclaimed De Simone Probiotic in India, expands GI portfolio

The formulation is backed by over 80 clinical trials and 200 scientific publications

Mankind Pharma inks licencing pact with Actimed to bring cachexia treatments to South Asia

The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands

Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD

The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

Healthium partners with US-based Tisgenx to bring cardiac innovations to India

This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment

Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment

Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion

Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China

Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)

Pfizer completes licensing agreement with 3SBio to expand oncology portfolio

3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio